Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis

No approved therapies are available for nonalcoholic steatohepatitis (NASH). Adenosine monophosphate–activated protein kinase (AMPK) is a central regulator of cell metabolism; its activation has been suggested as a therapeutic approach to NASH. Here we aimed to fully characterize the potential for direct AMPK activation in preclinical models and to determine mechanisms that could contribute to efficacy for this disease. A novel small‐molecule direct AMPK activator, PXL770, was used. Enzyme activity was measured with recombinant complexes. De novo lipogenesis (DNL) was quantitated in vivo and in mouse and human primary hepatocytes. Metabolic efficacy was assessed in ob/ob and high‐fat diet–fed mice. Liver histology, biochemical measures, and immune cell profiling were assessed in diet‐induced NASH mice. Direct effects on inflammation and fibrogenesis were assessed using primary mouse and human hepatic stellate cells, mouse adipose tissue explants, and human immune cells. PXL770 directly activated AMPK in vitro and reduced DNL in primary hepatocytes. In rodent models with metabolic syndrome, PXL770 improved glycemia, dyslipidemia, and insulin resistance. In mice with NASH, PXL770 reduced hepatic steatosis, ballooning, inflammation, and fibrogenesis. PXL770 exhibited direct inhibitory effects on pro‐inflammatory cytokine production and activation of primary hepatic stellate cells. Conclusion: In rodent models, direct activation of AMPK is sufficient to produce improvements in all core components of NASH and to ameliorate related hyperglycemia, dyslipidemia, and systemic inflammation. Novel properties of direct AMPK activation were also unveiled: improved insulin resistance and direct suppression of inflammation and fibrogenesis. Given effects also documented in human cells (reduced DNL, suppression of inflammation and stellate cell activation), these studies support the potential for direct AMPK activation to effectively treat patients with NASH.

[1]  A. Saltiel,et al.  From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases , 2020, The Journal of Biological Chemistry.

[2]  B. Viollet,et al.  Activation of Adenosine Monophosphate—Activated Protein Kinase Reduces the Onset of Diet‐Induced Hepatocellular Carcinoma in Mice , 2020, Hepatology communications.

[3]  I. Mikaelian,et al.  Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. , 2020, Journal of hepatology.

[4]  T. Cotter,et al.  Nonalcoholic Fatty Liver Disease 2020: The State of the Disease , 2020 .

[5]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[6]  M. Karin,et al.  An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis , 2020, Science.

[7]  L. Vonghia,et al.  Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease , 2019, Front. Immunol..

[8]  D. Carling,et al.  AMP-activated protein kinase: the current landscape for drug development , 2019, Nature Reviews Drug Discovery.

[9]  E. Dirinck,et al.  The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity , 2019, Front. Immunol..

[10]  Christian M. Metallo,et al.  Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD , 2019, Cell reports.

[11]  E. Degerman,et al.  AMPK activation by A-769662 and 991 does not affect catecholamine-induced lipolysis in human adipocytes. , 2018, American journal of physiology. Endocrinology and metabolism.

[12]  D. Schuppan,et al.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2018, Nature Reviews Gastroenterology & Hepatology.

[13]  H. Xu,et al.  Conformational heterogeneity of the allosteric drug and metabolite (ADaM) site in AMP-activated protein kinase (AMPK) , 2018, The Journal of Biological Chemistry.

[14]  Myung-Shik Lee,et al.  Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches , 2018, Front. Endocrinol..

[15]  A. Feldstein,et al.  Triggering and resolution of inflammation in NASH , 2018, Nature Reviews Gastroenterology & Hepatology.

[16]  M. Birnbaum,et al.  Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models , 2018, EBioMedicine.

[17]  M. Gillum,et al.  Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis , 2018, World journal of gastroenterology.

[18]  B. Viollet,et al.  AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development , 2018, EBioMedicine.

[19]  B. Hoogwerf,et al.  Non‐alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes , 2017, Diabetes, obesity & metabolism.

[20]  M. Erion,et al.  Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy , 2017, Science.

[21]  Wei Hu,et al.  AMPK: a novel target for treating hepatic fibrosis , 2017, Oncotarget.

[22]  K. Cusi,et al.  Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit , 2017, Hepatology.

[23]  B. Viollet,et al.  Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice. , 2017, Cell metabolism.

[24]  P. Muckett,et al.  Liver-Specific Activation of AMPK Prevents Steatosis on a High-Fructose Diet , 2017, Cell reports.

[25]  B. Viollet,et al.  Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation , 2017, Molecular and Cellular Endocrinology.

[26]  G. Steinberg,et al.  Treatment of nonalcoholic fatty liver disease: role of AMPK. , 2016, American journal of physiology. Endocrinology and metabolism.

[27]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[28]  J. Jelsing,et al.  Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. , 2016, World journal of hepatology.

[29]  H. Sul,et al.  AMPK Phosphorylates Desnutrin/ATGL and Hormone-Sensitive Lipase To Regulate Lipolysis and Fatty Acid Oxidation within Adipose Tissue , 2016, Molecular and Cellular Biology.

[30]  J. Suttles,et al.  Adenosine 5′-Monophosphate–Activated Protein Kinase Regulates IL-10–Mediated Anti-Inflammatory Signaling Pathways in Macrophages , 2015, The Journal of Immunology.

[31]  B. Kemp,et al.  Small molecule drug A-769662 and AMP synergistically activate naive AMPK independent of upstream kinase signaling. , 2014, Chemistry & biology.

[32]  J. Browning,et al.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.

[33]  David Carling,et al.  Structural basis of AMPK regulation by small molecule activators , 2013, Nature Communications.

[34]  J. Dyck,et al.  Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin–sensitizing effects of metformin , 2013, Nature Medicine.

[35]  A. Rehman,et al.  Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice , 2013, Hepatology.

[36]  David Carling,et al.  AMPK, insulin resistance, and the metabolic syndrome. , 2013, The Journal of clinical investigation.

[37]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[38]  C. Apovian,et al.  Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue[S] , 2012, Journal of Lipid Research.

[39]  B. Kemp,et al.  Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. , 2011, The Journal of clinical investigation.

[40]  T. Luedde,et al.  NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.

[41]  C. Apovian,et al.  Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. , 2011, Biochemical and biophysical research communications.

[42]  M. Erion,et al.  A Potent and Selective AMPK Activator That Inhibits de Novo Lipogenesis. , 2010, ACS medicinal chemistry letters.

[43]  B. Viollet,et al.  Development of hepatic fibrosis occurs normally in AMPK-deficient mice. , 2010, Clinical science.

[44]  J. Suttles,et al.  Adenosine 5′-Monophosphate-Activated Protein Kinase Promotes Macrophage Polarization to an Anti-Inflammatory Functional Phenotype1 , 2008, The Journal of Immunology.

[45]  D. Brenner,et al.  High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate–activated protein kinase , 2008, Hepatology.

[46]  S. Gelmini,et al.  Adenosine monophosphate–activated protein kinase modulates the activated phenotype of hepatic stellate cells , 2007, Hepatology.

[47]  R. Heath,et al.  Defining the Mechanism of Activation of AMP-activated Protein Kinase by the Small Molecule A-769662, a Member of the Thienopyridone Family* , 2007, Journal of Biological Chemistry.

[48]  D. Carling,et al.  Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. , 2007, The Biochemical journal.

[49]  David Carling,et al.  Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. , 2006, Cell metabolism.

[50]  L. Kifle,et al.  Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. , 2006, Cell metabolism.

[51]  C. Heldin,et al.  Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.

[52]  C. Heldin,et al.  Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. , 1997, Nature.